AUTL Autolus Therapeutics plc
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1730463 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY168.8%
TTM net income YoY-13.9%
TTM EPS YoY-15.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin35.8%
Operating margin-159.6%
Net margin-186.4%
FCF margin-131.1%
EBITDA margin-153.1%
Returns
ROE-174.9%
ROA-43.2%
ROIC (approx.)—
Asset turnover0.23x
Leverage & solvency
Liabilities / assets94.8%
Debt / equity0.00x
Current ratio3.72x
Interest coverage-4.79x
Cash quality & payout
Operating cash flow / net income0.69x
Accruals ratio-13.5%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $41.24M | $45.69M | $26.22M | $24.29M | $21.19M | $20.92M | $8.98M | $29,000 |
| Cost of revenue | $17.93M | $20.47M | $24.57M | $25.33M | $28.64M | $24.45M | $17.95M | $11.39M |
| Gross profit | $23.31M | $25.22M | $1.65M | -$1.04M | -$7.45M | -$3.52M | -$8.97M | -$11.36M |
| R&D expense | $30.90M | $27.90M | $21.21M | $35.63M | $27.89M | $27.43M | $26.73M | $30.83M |
| SG&A expense | $35.95M | $41.16M | $39.95M | $35.80M | $36.28M | $30.27M | $29.54M | $33.68M |
| Operating income | -$43.53M | -$43.84M | -$59.51M | -$72.47M | -$71.62M | -$61.22M | -$65.24M | -$75.86M |
| Interest expense | $14.53M | -$2.67M | $11.12M | $22.84M | $10.52M | -$6.83M | $10.14M | -$30.84M |
| Pretax income | -$55.58M | -$38.65M | -$70.73M | -$91.52M | -$78.59M | -$47.52M | -$67.94M | -$26.14M |
| Income tax | -$489,000 | $465,000 | $863,000 | -$1.18M | $532,000 | $397,000 | $2.23M | $1.46M |
| Net income | -$55.09M | -$39.11M | -$71.60M | -$90.33M | -$79.12M | -$47.92M | -$70.16M | -$27.61M |
| EBITDA | -$41.13M | -$41.64M | -$57.30M | -$70.32M | -$69.52M | -$59.12M | -$63.25M | -$73.95M |
| EPS (basic) | -0.21 | -0.15 | -0.27 | — | -0.30 | -0.18 | -0.26 | — |
| EPS (diluted) | -0.21 | -0.15 | -0.27 | — | -0.30 | -0.18 | -0.26 | — |
| Weighted avg. shares (diluted) | 266.20M | 266.16M | 266.14M | — | 266.14M | 266.14M | 266.13M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $245.41M | $171.41M | $130.93M | $104.13M | $86.12M | $123.83M | $95.80M | $228.80M |
| Short-term investments | $2.97M | $30.22M | $98.51M | $196.58M | $281.29M | $330.45M | $420.78M | $360.64M |
| Receivables | $38.00M | $44.39M | $27.66M | $24.02M | — | — | — | $15,000 |
| Inventory | $35.02M | $33.43M | $33.23M | $33.21M | $27.72M | $23.94M | $14.65M | $4.14M |
| Current assets | $366.78M | $336.09M | $368.83M | $435.92M | $514.58M | $574.25M | $615.77M | $660.93M |
| PP&E, net | $59.66M | $60.52M | $61.91M | $63.56M | $66.85M | $66.47M | $57.97M | $49.55M |
| Intangibles | $18.07M | $18.53M | $18.98M | $19.81M | $20.28M | $12.93M | $12.47M | $12.37M |
| Total assets | $523.06M | $493.23M | $527.07M | $589.07M | $661.95M | $720.98M | $746.34M | $782.73M |
| Current liabilities | $98.65M | $68.79M | $63.60M | $73.44M | $83.07M | $68.15M | $66.61M | $60.74M |
| Total liabilities | $495.66M | $418.39M | $418.24M | $410.94M | $396.50M | $374.52M | $375.23M | $355.40M |
| Shareholders' equity | $27.40M | $74.84M | $108.83M | $178.13M | $265.45M | $346.46M | $371.11M | $427.32M |
| Cash flow statement | ||||||||
| Operating cash flow | -$18.53M | -$25.07M | -$65.32M | -$67.32M | -$67.90M | -$72.78M | -$75.56M | -$37.93M |
| Capital expenditure | $1.25M | $913,000 | $2.69M | -$885,000 | $4.41M | $7.28M | $8.24M | $11.11M |
| Free cash flow | -$19.78M | -$25.98M | -$68.00M | -$66.44M | -$72.31M | -$80.06M | -$83.81M | -$49.05M |
| Investing cash flow | $25.99M | $67.90M | $96.15M | $86.54M | $35.55M | $95.92M | -$59.55M | -$383.59M |
| Financing cash flow | $67.33M | -$2.14M | -$2.06M | -$1.80M | -$1.77M | -$768,000 | $0 | $30.01M |
| Depreciation & amortization | $2.40M | $2.20M | $2.21M | $2.14M | $2.10M | $2.10M | $1.99M | $1.92M |
| Stock-based compensation | $2.73M | $4.59M | $3.56M | $3.44M | $3.83M | $4.29M | $2.87M | $6.23M |
Free plan shows the latest 8 periods; Pro shows all 33 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.